IGI licenses ISB 2001 to AbbVie for cancer and autoimmune diseases, with $700M upfront and milestone-based payments.

• ISB 2001, built on IGI’s BEAT platform, targets hard-to-treat cancers with multispecific, trispecific antibody technology.
• AbbVie gains global rights to develop, manufacture, and market ISB 2001 in major regions, including the U.S., the EU, and China.
• IGI to receive up to $1.925B in total payments plus double-digit royalties, boosting its next-gen oncology pipeline.